Molecules, 2021 Three decades ago, dye-sensitized solar cells (DSSCs) emerged as a method for harnessing the energy of the sun and for converting it into electricity. Since then, a lot of work has been devoted to create better global photovoltaic efficiencies and long ...
Luca Mauri +4 more
doaj +1 more source
Heterodinuclear ruthenium(II)-cobalt(III) complexes as models for a new approach to selective cancer treatment [PDF]
, 2012 Heterodinuclear ruthenium(ii)-cobalt(iii) complexes have been prepared as part of investigations into a new approach to selective cancer treatment. A cobalt(iii) centre bearing amine ligands, which serve as models for cytotoxic nitrogen mustard ligands ...
Alan M. Downward +43 more
core +1 more source
Coordination of di- and triimine ligands at ruthenium(II) and ruthenium(III) centers: structural, electrochemical and radical scavenging studies [PDF]
, 2016 Herein, we explore the coordination of di- and triimine chelators at ruthenium(II) and ruthenium(III) centers. The reactions of 2,6-bis-((4- tetrahydropyranimino)methyl)pyridine (thppy), N1,N2-bis((3-chromone) methylene)benzene-1,2-diamine (chb), and ...
Adebisi, Abimbola A. +4 more
core +2 more sources
Anticancer and antiproliferative activity of ruthenium complex (II) bearing 3,3’-dicarboxy-2,2’-bipyridine ligand [PDF]
Pharmacia, 2023 Even though significant progress has been made in cancer treatment, there is always room for improvement. The experimental drug Ruthenium Complex II shows promise as a cancer treatment.
Mohamed Saadh
doaj +3 more sources
Unusual DNA binding modes for metal anticancer complexes [PDF]
, 2009 DNA is believed to be the primary target for many metal-based drugs. For example, platinum-based anticancer drugs can form specific lesions on DNA that induce apoptosis.
Pizarro, Ana M., Sadler, P. J.
core +1 more source
Controlling platinum, ruthenium, and osmium reactivity for anticancer drug design [PDF]
, 2009 The main task of the medicinal chemist is to design molecules that interact specifically with derailed or degenerating processes in a diseased organism, translating the available knowledge of pathobiochemical and physiological data into chemically ...
Bruijnincx, Pieter C. A., Sadler, P. J.
core +1 more source
New trends for metal complexes with anticancer activity [PDF]
, 2008 Medicinal inorganic chemistry can exploit the unique properties of metal ions for the design of new drugs. This has, for instance, led to the clinical application of chemotherapeutic agents for cancer treatment, such as cisplatin. The use of cisplatin is,
Ang +56 more
core +1 more source
Asymmetric transfer hydrogenation of acetophenone derivatives using 2-benzyl-tethered ruthenium (II)/TsDPEN complexes bearing η6-(p-OR) (R = H, iPr, Bn, Ph) ligands [PDF]
, 2018 A series of 4′-OR (R = H, iPr, Bn, Ph) substituted ruthenium (II) biphenyl TsDPEN complexes are described; the complexes are accessed via an operationally simple and reliable two-step ligand synthesis followed by ligation to the ruthenium (II) centre. We
Bhanage, Bhalchandra M. +4 more
core +1 more source
Arene Ruthenium(II) Complexes with Phosphorous Ligands as Possible Anticancer Agents.
Chimia (Basel), 2017 Ruthenium(II) complexes of formula [Ru(η6-arene)Cl2 (PTA)] (RAPTA) are potential anticancer drugs with notable antimetastatic and antiangiogenic activity, which are now pointing to clinical trials. Following the great interest aroused by these compounds,
L. Biancalana +2 more
semanticscholar +1 more source
Synthesis, Characterization, and Properties of Mononuclear and Dinuclear Ruthenium(II) Complexes Containing Phenanthroline and Chlorophenanthroline [PDF]
, 2013 The study of photophysical and photochemical properties of ruthenium complexes is of great interest for fundamental practical reasons. Ruthenium complexes have been investigated for use in artificial photosynthesis.
Bhuiyan, Anwar A., Du, X.
core +3 more sources